Navigating MS Treatment: The Role of Infusion Therapies
Published: Nov 06, 2023
Infusion therapies offer a potent approach to managing multiple sclerosis, but what should patients expect during treatment? Let's break it down.
Contents
What Are Infusion Therapies?
Infusion therapies involve administering medication directly into the bloodstream through an IV, allowing for precise dosing and rapid effects. For MS, these therapies include drugs like natalizumab and ocrelizumab, which target specific components of the immune system. They are often used in patients with active disease who need high-efficacy treatments.
The Infusion Process
Before starting an infusion, patients undergo screening for potential risk factors, such as infections. The infusion process typically involves premedication to prevent reactions, followed by the drug infusion under medical supervision. The procedure can take several hours, and patients are monitored for side effects during and after the infusion.
Benefits and Considerations
Infusion therapies can offer significant benefits, including reduced relapse rates and improved disease control. However, they require regular healthcare visits and carry risks such as infusion reactions and infections. Patients should discuss the pros and cons with their healthcare provider to determine the best approach for their MS management.
Frequently Asked Questions
It's a method of delivering medication directly into the bloodstream.
To prevent infusion reactions during the therapy.
The process can take several hours under medical supervision.
They reduce relapse rates and improve disease control.
Key Takeaways
Infusion therapies are a powerful tool in MS treatment, providing significant benefits for many patients.
Consult Doctronic to learn more about infusion therapies and their role in your MS treatment plan.Related Articles
References
Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748.
Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 2021; 78:736.
Always discuss health information with your healthcare provider.